96. Crohn disease Clinical trials / Disease details

Clinical trials : 2,442 / Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2015-001678-17-NL (EUCTR)	14/01/2016	14/01/2016	A Pilot Study of FFP104 in Subjects with Crohn’s Disease	A Phase II, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Pilot Study to Evaluate the Safety and Efficacy of FFP104 in the Treatment of Subjects with Moderate to Severely Active Crohn’s Disease	Moderate to Severely Active Crohn’s disease;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Code: FFP104	Fast Forward Pharmaceuticals, B.V.	NULL	Not Recruiting			Female: yes Male: yes	24	Phase 2	Belgium;Netherlands
2	NCT02465944 (ClinicalTrials.gov)	January 2016	18/5/2015	A Pilot Study of FFP104 in Subjects With Crohn's Disease	A Phase II, Double-blind, Randomised, Placebo-controlled, Parallel Group Pilot Study to Evaluate the Safety and Efficacy of FFP104 in the Treatment of Subjects With Moderate to Severely Active Crohn's Disease	Crohn's Disease	Drug: FFP104;Drug: Placebo	Fast Forward Pharmaceuticals	NULL	Recruiting	18 Years	75 Years	Both	24	Phase 1/Phase 2	Belgium;Netherlands
3	EUCTR2015-001678-17-BE (EUCTR)	01/12/2015	10/09/2015	A Pilot Study of FFP104 in Subjects with Crohn’s Disease	A Phase II, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Pilot Study to Evaluate the Safety and Efficacy of FFP104 in the Treatment of Subjects with Moderate to Severely Active Crohn’s Disease	Moderate to Severely Active Crohn’s disease;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Code: FFP104	Fast Forward Pharmaceuticals, B.V.	NULL	Not Recruiting			Female: yes Male: yes	24	Phase 2	Belgium;Netherlands